Clinics in Dermatology
Volume 27, Issue 4 , Pages 339-345 , July 2009

The ethics of consulting with pharmaceutical companies

  • Andrew Miner, BS

      Affiliations

    • The University of Texas Southwestern, Dallas, TX, USA
    • ,
  • Alan Menter, MD

      Affiliations

    • Division of Dermatology, Baylor University Medical Center, 3900 Junius Street, Suite 145, Dallas, TX 75246, USA
    • Corresponding Author InformationCorresponding author.

References 

  1. Sneader W. The discovery of aspirin: a reappraisal. BMJ. 2000;321:1591–1594
  2. Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PD, Blumenthal D. A national survey of physician-industry relationships. New Engl J Med. 2007;356:1742–1750
  3. Campbell EG. Doctors and drug companies–scrutinizing influential relationships. N Engl J Med. 2007;357:1796–1797
  4. Ross JS, Lackner JE, Lurie P, Gross CP, Wolfe S, Krumholz HM. Pharmaceutical company payments to physicians. JAMA. 2007;297:1216–1223
  5. Tattersall M, Kerridge I. The drug industry and medical professionalism. Lancet. 2006;367:28
  6. Rothman DJ. Medical professionalism–focusing on the real issues. N Engl J Med. 2000;342:1284–1286
  7. Sismondo S. How pharmaceutical industry funding affects trial outcomes: causal structures and responses. Soc Sci Med. 2008;66:1909–1914
  8. Brennan TA, Rothman DJ, Blank L, et al. Health industry practices that create conflicts of interest. JAMA. 2006;295:429–433
  9. Jesitus J. A complicated web. Dermatol Times. 2008;32–35
  10. Council on Ethical and Judicial Affairs, American Medical Association . CEJA Report G–I-90: gifts to physicians from industry. JAMA. 1991;265:501
  11. Katz KA. Time to nip ‘seeding trials’ in the bud. Arch Dermatol. 2008;144:403–404
  12. American Academy of Dermatology . Administrative regulation: code of medical ethics for dermatologists section III-C. 2005;
  13. Feder BJ. Artificial-joint makers settle kickback case. NY: Times; 2007;
  14. Burns LR. Dealing with innovation and costs in orthopedics: a conversation with Dane Miller. Health Affairs. 2006;25:w241–w251
  15. Ross JR, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib. JAMA. 2008;299:1800–1812
  16. Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment. JAMA. 2008;299:1813–1817
  17. DeAngelis CD, Fontanarosa PB. Impugning the integrity of medical science. JAMA. 2008;299:1833–1835
  18. Newburger AE, Caplan AL. Taking ethics seriously in cosmetic dermatology. Arch Dermatol. 2006;142:1641–1642
  19. Webster SB. Professionalism and medical ethics in dermatology–2000. Arch Dermatol. 2000;136:101–102
  20. Chaudhry S, Schroter S, Smith R, Morris J. Does declaration of competing interests affect readers' perceptions? A randomised trial. BMJ. 2002;325:1391–1392
  21. Kolata G. Citing ethics, some doctors are rejecting industry pay. NY: Times; 2008;
  22. American Medical Association . Code of Medical Ethics Principle V. 2001;
  23. Holden C. NEJM admits to breaking its own tough rules. Science. 2000;287:1573

PII: S0738-081X(09)00024-8

doi: 10.1016/j.clindermatol.2009.02.004

Clinics in Dermatology
Volume 27, Issue 4 , Pages 339-345 , July 2009

Article Tools